Abstract
BACKGROUND AND PURPOSEHigh-grade gliomas are highly malignant, aggressive, high incidence rate, and mortality. The purpose of this study was to analyze retrospectively and identify prognostic factors of patients with high-grade gliomas diagnosed by biopsy or postoperative pathological examination. METHODSIn this retrospective study, we analyzed the patient’s demographic data, tumor characteristics, treatment approaches, immunocytochemistry results, the overall survival (OS) time, and the progression-free survival (PFS) time in a series of 159 histologically proven high-grade gliomas recruited from January 2011 to December 2019. OS time and PFS time were analyzed by Kaplan-Meier survival analysis with log-rank test and found the independent factors by using Cox regression analysis. RESULTSSurvival analysis showed that an OS of 84.90%, 55.35% and 13.20% was observed at 1, 2 and 5 years, respectively. And a PFS of 56.6%, 25.26% and 3.14% was observed at 1, 2 and 5 years, respectively. The mean OS was 52.73 months and mOS was 35 months. Univariate analysis showed that postoperative pathological classification and grade and age were statistically significant for patient outcome (P < 0.01). 147 patients underwent concurrent chemoradiotherapy and 80 of them died; 12 patients did not undergo concurrent chemoradiotherapy and 10 died (P = 0.03); There were statistically significant differences in the prognostic impact of Ki-67 expression, MGMT, IDH1R132H and p53 mutations by immunohistochemistry (P = 0.001; P = 0.016; P = 0.003; and P = 0.021, respectively). Similarly, we concluded that different grades, age, pathological classification, Ki-67 and IDH1R132H expression by immunohistochemistry were statistically significantly associated with PFS (P < 0.01; P = 0.004; P = 0.003; P = 0.001; P = 0.028). CONCLUSIONSTumor grade and concurrent chemoradiotherapy after surgery were independent prognostic factors affecting patients’ survival, and grade was also an independent factor affecting PFS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
